Dental management in patient taking non-vitamin k antagonist oral anticoagulants
Article Sidebar
Main Article Content
Abstract
Vitamin K antagonist oral anticoagulants, such as warfarin, have been used to prevent and treat thromboembolic events. In addition to the therapeutic efficacy, warfarin also has limitations. Currently, a new group of oral anticoagulants: non-Vitamin K antagonist oral anticoagulants (NOACs) are developed and giving patients more options for treatment. Many studies have found that these drugs are more effective or equal to warfarin. Although, the management of non-Vitamin K antagonist oral anticoagulants in patients undergoing dental procedures was not clear. Therefore, the objective of this article is to review the clinical practice guidelines for this group of patients.
Article Details
References
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015; 11: 967-77.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51. Erratum in: N Engl J Med 2010; 363(19): 1877.
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-92.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013; 369: 2093-104.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-91.
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-93.
Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac Surg 2016; 45: 618-30.
สำนักานคณะกรรมการอาหารและยา. รายการยาใหม่แบบมีเงื่อนไข (NC) ที่ได้รับการอนุมัติทะเบียน ปี พ.ศ. 2557 จากข้อมูลในระบบของ อย. Available from: http://www.fda.moph.go.th/sites/drug/EN/Zone_service/con_57.pdf. online 23 August 2019.
U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=022512. online 23 August 2019.
Yorkgitis BK, Zhang J, Rappold JF. Non–Vitamin K Antagonist Oral Anticoagulants: The Clinician’s New Challenge. J Am Osteopath Assoc 2015; 115: 612-21.
The Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD). Available from: https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. online 23 August 2019.
กมลวรรณ เข็มกำเหนิด. Rivaroxaban. J Prapokklao Hosp Clin Med Educat Center 2014; 31: 137-41.
Drugs.com. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Available from: https://www.drugs.com/newdrugs/fda-approves-eliquis-apixaban-deep-vein-thrombosis-pulmonary-embolism-4073.html. online 23 August 2019.
U.S. Food and Drug Administration. Drug Trials Snapshot: Savaysa (edoxaban) for Prevention of Stroke in Atrial Fibrillation. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-savaysa-edoxaban-prevention-stroke-atrial-fibrillation. online 23 August 2019.
Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants. J Am Coll Cardiol 2014; 64: 1128–39.
Hawes E, Deal A, Funk‐Adcock D, Gosselin R, Jeanneret C, Cook A, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-502.
Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg E-M, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69: 1875-81.
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 127: 348-8. Erratum in: Circulation 2012; 126(10): e160.
Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124: 3692-8.
Lababidi E, Breik O, Savage J, Engelbrecht H, Kumar R, Crossley CW. Assessing an oral surgery specific protocol for patients on direct oral anticoagulants: a retrospective controlled cohort study. Int J Oral Maxillofac Surg 2018; 47: 940-6.
Berton F, Costantinides F, Rizzo R, Franco A, Contarin J, Stacchi C, et al. Should we fear direct oral anticoagulants more than vitamin K antagonists in simple single tooth extraction? A prospective comparative study. Clin Oral Investig 2019; 23: 3183-92.
Andrade MVS, Andrade LAP, Bispo AF, Freitas LA, Andrade MQS, Feitosa GS, et al. Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures. Arq Bras Cardiol 2018; 111: 394-9.
Yagyuu T, Kawakami M, Ueyama Y, Imada M, Kurihara M, Matsusue Y, et al. Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study. BMJ Open 2017; 7: e015952.
Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment. A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122: e146-e55.
Clemm R, Neukam F, Rusche B, Bauersachs A, Musazada S, Schmitt C. Management of anticoagulated patients in implant therapy: A clinical comparative study. Clin Oral Implants Res 2016; 27: 1274-82.
Pollack Jr CV, Reilly PA, Van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017; 377: 431-41.
Connolly SJ, Milling Jr TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131-41.
Awad NI, Cocchio C. Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. P T 2013; 38: 696-8, 701.
Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care 2016; 20: 115.
Amy S. Update on Reversal Agents for Novel Oral Anticoagulants. Available from: https://www.acc.org/latest-in-cardiology/articles/2015/12/11/08/20/update-on-reversal-agents-for-novel-oral-anticoagulants. online 23 August 2019.
Raval AN, Cigarroa JE, Chung MK, Diaz LJ, Diercks D, Piccini JP, et al. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation 2017; 135: e604-e33. Erratum in: Circulation 2017; 135(10): e647, Circulation 2017; 135(24): e1144.
Cocero N, Basso M, Grosso S, Carossa S. Direct Oral Anticoagulants (DOACs) and Medical Comorbidities in Patients Needing Dental Extractions: Management of the Risk of Bleeding. J Oral Maxillofac Surg 2019; 77: 463-70.
Gómez-Moreno G, Aguilar-Salvatierra A, Fernández-Cejas E, Delgado-Ruiz RA, Markovic A, Calvo-Guirado JL. Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clin Oral Implants Res 2016; 27: 730-3.
Gómez-Moreno G, Fernández-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res 2018; 29: 644-8.
Hanken H, Gröbe A, Heiland M, Smeets R, Kluwe L, Wikner J, et al. Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Investig 2016; 20: 1279-82.
Miller S, Miller C. Direct oral anticoagulants: A retrospective study of bleeding, behavior, and documentation. Oral Dis 2018; 24: 243-8.
Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116: e191-e5.